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BACKGROUND: The objective of this study was 
to describe the cost of prior diagnostic evalua- 
tion in patients referred for evaluation of synco- 
pe whose history was typical of vasodepressor 
syncope. 
METHODSANDRESULTS: Thirtyconsecutivepa- 
tients who were referred for evaluation of syn- 
cope of undetermined origin and whose history 
was highly suggestive of vasodepressor syncope 
participated in this study. These 30 patients rep- 
resented 19% of 158 patients referred for evalu- 
ation of syncope during the period of enroll- 
ment. All patients had positive results of an 
upright-tilt test, confirming the diagnosis of va- 
sodepressor syncope. At the time of evaluation, 
the type and results of all diagnostic tests that 
had been performed prior to referral were re- 
corded for each patient. The cost of diagnostic 
testing was then determined based on the 1991 
cost of these tests at the University of Michigan 
Medical Center. 
A mean of 4 f 2 major diagnostic tests were 
performed before referral to the University of 
Michigan Medical Center. The mean and median 
costs of diagnostic testing per patient prior to 
referral were $3,763 f 3,820 and $2,673 (range: 0 
to $16,606) respectively. Sii patients underwent 
no major diagnostic tests prior to referral and, 
therefore, the cost of major diagnostic testing 
was zero in these patients. In the remaining pa- 
tients, the mean and median costs of diagnostic 
testing per patient were $4,704 f 3,713 and $3,777 
(range: $1,025 to $16,606) respectively. 
CONCLUSIONS: The results of this study demon- 
strate that a diagnosis of vasodepressor syncope 
can be established clinically in approximately 
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20% of patients referred to a university hospital 
for evaluation of syncope of undetermined ori- 
gin. Failure to recognize the clinical features of 
vasodepressor syncope in these patients resulted 
in up to $16,000 of unnecessary diagnostic test- 
ing. A greater awareness of the clinical features 
of vasodepressor syncope may, therefore, result 
in significant economic savings. 
V asodepressor syncope is extremely common, accounting for up to 40% of cases of syncope 
[l-5]. Typical vasodepressor syncope can be diag- 
nosed based on historical features of the episode 
[l-5]. We have noted that many patients referred 
for evaluation of syncope already have undergone 
extensive diagnostic testing despite a history 
strongly suggestive of vasodepressor syncope. In 
these patients, the failure to recognize the clinical 
features of vasodepressor syncope led to an expen- 
sive diagnostic evaluation that unnecessarily in- 
creased the cost of medical care. 
The purpose of this study was to describe the cost 
of prior diagnostic evaluation in patients referred 
for the evaluation of syncope whose history was 
typical of vasodepressor syncope. Our aim is to 
highlight the potential savings that would result 
from a heightened awareness of the clinical features 
of vasodepressor syncope. 
PATIENTS AND METHODS 
Thirty consecutive patients who were referred to 
the University of Michigan for evaluation of synco- 
pe of undetermined origin between September 1989 
and July 1991 and whose history was highly sugges- 
tive of vasodepressor syncope participated in this 
study. These 30 patients represented 19% of 158 
patients referred to the University of Michigan for 
evaluation of syncope during this time period. Each 
patient underwent an upright-tilt-table test to con- 
firm the diagnosis of vasodepressor syncope [6-121. 
At the time of evaluation, the type and results of all 
diagnostic tests that had been performed prior to 
referral were recorded for each patient. 
There were 16 men and 14 women and their mean 
age was 39 f 16 years (f standard deviation; range: 
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TABLE I 
Symptoms in 30 Patients With Vasodepressor Syncope 
No. of Prevalence 
Symptom Patients (%I 
Identifiable precipitant 10 33 
Upright position 28 93 
Prodromal symptoms 30 100 
Nausea 
Warmth :; Fl 
Lightheadedness 21 
Constriction of visual fields 14 iv 
Epigastric discomfort 
Premonition of syncope 2: 2 
Pallor 20 100” 
No injury 18 60 
Residual symptoms 100 
Weakness ;i 
L$hkdedness 12 ii 
40 
Diaphoresis i: 
No confusion 27 !z 
allor was observed in each of the 20 patients who had a witnessed syncopal episode. 
17 to 71 years). Twenty-six patients had no history 
of structural heart disease, 2 patients had mitral 
valve prolapse, and 2 patients had a history of hy- 
pertension. Each patient had experienced one or 
more episodes of syncope. Twelve patients had 
greater than 10 syncopal episodes. The mean num- 
ber of syncopal episodes in the remaining patients 
was 4 f 2. Four of these patients had experienced 
only a single episode of syncope. 
Clinical Diagnosis of Vasodepressor Syncope 
At the time of evaluation, each patient was inter- 
viewed using a standard questionnaire. The ques- 
tionnaire was designed to determine the likelihood 
of vasodepressor syncope by reviewing the past 
medical history and the historical details of the syn- 
copal episodes. The patients were asked a series of 
specific questions to identify precipitating factors, 
position and activity prior to syncope, color and 
appearance during syncope, resultant injury, and 
the type and duration of prodromal and residual 
symptoms. In addition, patients were asked to give 
a detailed account of their two most recent episodes 
of syncope. Based on their response to this ques- 
tionnaire, each patient in this study was clinically 
diagnosed as having vasodepressor syncope. Symp- 
toms that were believed to be suggestive of vaso- 
depressor syncope included: (1) the presence of an 
obvious precipitant such as pain, fear, emotional 
stress, alcohol, or a large meal; (2) syncope occur- 
ring only in the standing or seated position; (3) the 
presence of typical prodromal symptoms including 
nausea, warmth, lightheadedness, weakness, dia- 
phoresis, constriction of the visual fields, epigastric 
discomfort, and/or a sensation of an impending 
faint for at least 5 seconds prior to syncope; (4) the 
observation by a bystander of pallor during synco- 
pe; (5) the absence of significant injury; (6) the pres- 
ence of typical residual symptoms including weak- 
ness, lightheadedness, nausea, and fatigue lasting 
minutes to hours; and (7) the absence of confusion 
in the recovery period [l-5,13-16]. Patients were 
diagnosed as having vasodepressor syncope if they 
had a normal electrocardiogram, no significant his- 
tory of cardiovascular disease, and the presence of 
signs or symptoms from five or more categories. The 
frequency with which each of these symptoms was 
reported by the patients is shown in Table I. 
Upright-Tilt Testing 
Upright-tilt testing was performed in the fasting 
state. The patients were connected to a standard 
cardiac monitor and an automatic sphygmoma- 
nometer, and were placed on a motorized table with 
a foot board for weight bearing. Passive upright tilt 
to 70” was performed in the drug-free state for 15 
minutes. If the patients’ symptoms were not repro- 
duced, upright tilt was repeated for 15 minutes dur- 
ing an infusion of 4 pg/min of isoproterenol. The 
patients’ blood pressure was recorded in the supine 
position, 1 minute following tilt, and thereafter at 5- 
minute intervals. If symptoms developed, blood 
pressure was recorded at l-minute intervals. The 
patients’ electrogram was continuously monitored 
during the procedure. A rhythm strip was recorded 
at 5-minute intervals, then continuously with the 
development of symptoms. A positive response to 
upright tilt was defined as the development of pre- 
syncope or syncope associated with hypotension 
and an absolute or relative bradycardia. A relative 
bradycardia was defined as greater than a 5 beat per 
minute decrease in heart rate from the peak 
achieved heart rate. The test was terminated if the 
patient developed chest pain or severe discomfort. 
There were no complications during or following 
upright-tilt testing. 
Each patient had a vasodepressor response to up- 
right-tilt testing that reproduced their clinical 
symptoms. Five patients developed a vasodepressor 
response to upright tilt alone and 25 patients devel- 
oped a vasodepressor response to upright tilt in 
conjunction with an isoproterenol infusion. 
Clinical Follow4Jp 
If the frequency and severity of symptoms were 
believed to mandate therapy, patients were treated 
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TABLE II 





Holter monitor 28 (22*) 405 11,340 
Exercise stress test 14 328 4,592 
Thallium stress test 1 1,784 1,784 
Gated blood pool scan 2: 852 852 
Echocardiogram 697 13,940 
Cardiac catheterization 4 4,810 19,240 
Electrophysiology study 5 6,797 19,240 
Electroencephalogram 285 3,990 
Co&[;t&?,d tomography :z 3 1,504 886 14,176 512
Carotid Doppler scan 209 1,045 
Glucose tolerance test : 280 1,120 
Total diagnostic tests performed 76,591 
RI = magnetic resonance imaging. 
‘wenty-two patients underwent 28 Halter monitors. 
with pharmacologic or pacemaker therapy. The 
type of therapy was individualized and the efficacy 
of the therapy was guided by follow-up upright-tilt 
tests. Each patient was followed for a minimum of 6 
months to determine the frequency and type of re- 
current symptoms. 
Twenty-eight patients were treated with phar- 
macologic (n = 26), pacemaker (n = l), or combined 
pharmacologic and pacemaker therapy (n = 1) for 
prevention of recurrent syncope. Long-term thera- 
py was not believed to be necessary in two patients 
who had sustained only a single episode of syncope 
that was not associated with significant injury. Sev- 
enteen patients were treated long term with p 
blockers, 7 with disopyramide, 1 with aminophyl- 
line, and 2 with combination therapy. Twenty-nine 
of the 30 patients were contacted at a mean of 17 f 7 
months following their initial evaluation. Six pa- 
tients have experienced presyncope but no patient 
has had recurrent syncope during follow-up. 
Cost of Prior Syncope Evaluation 
The cost of major diagnostic tests performed as 
part of the syncope evaluation was estimated by 
determining the number and type of major diagnos- 
tic tests that had been obtained prior to referral. 
These data were obtained by interviewing the pa- 
tients at the time of their evaluation and also by 
contacting their referring physicians. Major diag- 
nostic tests included cardiac catheterization, elec- 
trophysiology tests, echocardiography, Holter mon- 
itoring, computerized tomographic (CT) scans of 
the head, electroencephalograms (EEGs), magnetic 
0 1 2 3 4 5 6 7 6 
Number of Major Diagnostic Tests per Patient 
Figure 1. The number of major diagnostic tests performed 
per patient. 
resonance imaging (MRI), glucose tolerance tests, 
and carotid Doppler studies. The cost of diagnostic 
testing was then determined based on the 1991 cost 
of these tests at the University of Michigan Medical 
Center. The cost of these tests included both the 
hospital charges and the physician’s interpretation 
fee. In this analysis, we did not include the cost of 




A mean of 4 f 2 major diagnostic tests were per- 
formed before referral to the University of Michi- 
gan Medical Center. The number and type of diag- 
nostic tests that were performed are shown in 
Table II. Holter monitoring was the most frequent- 
ly obtained diagnostic test, followed by echocardio- 
grams, CT scans of the head, and exercise tolerance 
tests. More than half of the patients underwent 
each of these tests. The distribution of the number 
of major diagnostic tests that were performed in 
each patient is shown in Figure 1. Six patients were 
directly referred for evaluation of suspected vaso- 
depressor syncope and underwent no major diag- 
nostic tests. The remaining 24 patients underwent a 
mean of 5 f 2 major diagnostic tests prior to refer- 
ral. Abnormalities detected using these tests in- 
cluded mitral valve prolapse in two patients, mild 
mitral regurgitation in one patient, left ventricular 
hypertrophy in one patient, lacunar cerebral in- 
farcts in one patient, paroxysmal atria1 fibrillation 
in one patient, wandering atria1 pacemaker in one 
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Cost of Diagnostic Testing per Patient ($) 
Figure 2. The cost of major diagnostic testing per patient. 
Shown on the horizontal axis is the cost of major diagnostic 
testing. Shown on the vertical axis are the percentage of pa- 
tients in each cost group. 
patient, sinus bradycardia in one patient, and non- 
specific EEG abnormalities in three patients. In no 
patient were these abnormalities thought to be di- 
agnostic of the cause of syncope [2]. 
Cost of Diagnostic Testing 
The cost of each diagnostic test, the total number 
performed, and the associated total expenditure for 
each type of test are shown in Table II. Electrophys- 
iology tests were the most expensive diagnostic 
tests followed by cardiac catheterizations, thallium 
stress tests, and MRI scans. 
The mean and median costs of diagnostic testing per 
patient prior to referral were $3,763 f 3,820 and $2,678 
(range: 0 to $16,606) respectively. The distribution of 
the cost for diagnostic testing is shown in Figure 2. 
The cost of prior evaluation exceeded $3,000 in more 
than one third of the patients. Six patients underwent 
no major diagnostic tests prior to referral and, therefore, 
the cost was zero in these patients. In the remaining 
patients, the mean and median costs of diagnostic test- 
ing per patient were $4,704 f 3,713 and $3,777 (range: 
$0,025 to $16,606) respectively. 
COMMENTS 
Main Findings 
An alarming rise in the cost of medical care in the 
United States has emphasized the importance of 
cost containment in the health care industry [17]. 
One method by which cost containment can be 
achieved is by the elimination of unnecessary diag- 
nostic tests [18]. The results of this study demon- 
strate that a significant proportion of patients who 
have vasodepressor syncope may be undergoing 
thousands of dollars’ worth of unnecessary diagnos- 
tic testing. Approximately 20% of patients referred 
to our institution for evaluation of syncope had a 
clinical history typical of vasodepressor syncope, 
with this diagnosis being confirmed by upright-tilt 
testing. Despite having a condition that was diag- 
nosable on a clinical basis, the majority of these 
patients underwent extensive neurologic and/or 
cardiovascular evaluation prior to referral. Given 
the fact that syncope is a common problem, ac- 
counting for 3% of emergency room visits and up to 
6% of hospital admissions [1,19], the results of this 
study suggest that an increased awareness of the 
typical clinical features of vasodepressor syncope 
could eliminate unnecessary and expensive diag- 
nostic testing in many patients, resulting in sub- 
stantial cost savings. 
Clinical Diagnosis of Vasodepressor Syncope 
The diagnosis of vasodepressor syncope depends 
on the recognition of historical features of the syn- 
copal episode [l-5,13,14]. Vasodepressor syncope 
typically occurs in the standing and/or seated posi- 
tion and is triggered by pain, fear, emotional stress, 
alcohol, and/or a large meal. Prior to syncope, the 
patient experiences prodromal symptoms such as 
nausea, warmth, lightheadedness, weakness, dia- 
phoresis, constriction of visual fields, epigastric dis- 
comfort, and/or a sensation of an impending faint. 
These symptoms usually persist for at least several 
seconds prior to syncope. While unconscious, the 
patient appears pallid. After regaining conscious- 
ness, the patient typically is not confused but expe- 
riences residual symptoms such as weakness, 
lightheadedness, nausea, and/or fatigue, which may 
last for minutes to hours. 
The relative importance of each of these symp- 
toms in establishing the diagnosis of vasodepressor 
syncope is uncertain. Some studies have required 
an identifiable precipitating factor to establish a 
diagnosis of vasodepressor syncope [2], whereas 
others have based the diagnosis on a general clinical 
impression of the patient’s history [1,3,4]. The stud- 
ies that have required identification of a precipitant 
report a lower incidence of vasodepressor syncope 
and a greater incidence of syncope of undetermined 
origin as compared to the studies in which the diag- 
nosis was based on the overall clinical impression. 
In this study, the diagnosis of vasodepressor synco- 
pe did not require identification of a precipitant, 
but was based on the presence of a constellation of 
signs and symptoms suggestive of vasodepressor 
syncope. In fact, a precipitant was identified in only 
one third of patients in this study. Yet, the response 
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of the patients to upright-tilt testing and their re- 
sponse to therapy support the diagnosis of vaso- 
depressor syncope. These findings suggest that cri- 
teria for vasodepressor syncope that require 
identification of a precipitating factor may be too 
rigid. 
The precise sensitivity and specificity of each of 
the individual symptoms that commonly occur dur- 
ing vasodepressor syncope have not been deter- 
mined. Although prodromal symptoms, residual 
symptoms, and pallor were uniformly present in the 
patients in this study (100% sensitivity), the speci- 
ficity of these clinical features in distinguishing va- 
sodepressor syncope from other causes of syncope is 
uncertain. Nevertheless, given the low cost of up- 
right-tilt testing and the prevalence of vasodepres- 
sor syncope, if these symptoms are present, it may 
be appropriate to perform an upright-tilt test be- 
fore embarking on an extensive neurologic and/or 
cardiac evaluation. 
Sensitivity, Specificity, and Reproducibility of Up 
right-Tilt Testing 
No prior study has evaluated the sensitivity of 
upright-tilt testing in patients with vasodepressor 
syncope, the diagnosis of which was based on clini- 
cal symptoms. However, previous studies have eval- 
uated the sensitivity and specificity of upright-tilt 
testing in patients with syncope of unknown origin. 
In the absence of isoproterenol, upright-tilt testing 
results in a positive (vasodepressor) response in 8% 
to 66% of patients with syncope and less than 10% of 
controls [6-12,20-221. The use of isoproterenol in 
conjunction with upright-tilt testing results in a 
positive response in 78% to 82% of patients with 
syncope [6,7,11,12,21,22]. The precise specificity of 
upright-tilt testing in conjunction with an isopro- 
terenol infusion remains uncertain. Kapoor and 
Brant [21] recently reported a positive response to 
upright-tilt in conjunction with an isoproterenol in- 
fusion in 21 of 40 control patients. In contrast, stud- 
ies by Sheldon and Killam [20], Almquist et al [6], 
and Grubb et al [12] reported positive responses to 
upright tilt in conjunction with an isoproterenol 
infusion in 0 of 15, 2 of 18, and 0 of 6 control 
patients. 
The uncertain specificity of upright-tilt testing 
in conjunction with an isoproterenol infusion has 
little impact on the findings of this study because 
the diagnosis of vasodepressor syncope in this 
study was established on a clinical basis. The ac- 
curacy of this clinical diagnosis of vasodepressor 
syncope is supported, but not proved, by both the 
presence of a positive response to upright-tilt 
testing (with reproduction of clinical symptoms 
in all patients) as well as their response to 
therapy. 
Economic Benefit of a Directed Approach to Vaso- 
depressor Syncope 
The majority of patients in this study underwent 
extensive diagnostic testing prior to referral. This 
suggests either an underappreciation by referring 
physicians of the clinical features of vasodepressor 
syncope or a reliance on excessively rigid clinical 
criteria for establishment of a diagnosis of vaso- 
depressor syncope. The extensive testing per- 
formed in these patients also suggests that physi- 
cians may be uncomfortable diagnosing “syncope of 
unknown origin” without performing several 
screening tests. The findings of previous studies 
that have demonstrated the low diagnostic yield 
and cost ineffectiveness of these diagnostic tests 
appear to have had little impact [2,5,19,22-261. This 
most likely reflects both the perceived need by phy- 
sicians and patients to establish a diagnosis and the 
widespread availability of diagnostic testing. 
Within the entire group of patients in this study, 
two subgroups emerged. The first, and larger group, 
underwent extensive evaluation prior to referral. In 
these patients, an average of five major diagnostic 
tests were performed at a cost of nearly $5,000 per 
patient, with the cost in individual patients being as 
high as $16,000. The second group of patients were 
referred directly for evaluation and demonstrate 
the potential economic savings of a more directed 
approach to vasodepressor syncope. In these pa- 
tients, the diagnosis of vasodepressor syncope was 
suspected on a clinical basis and was confirmed 
with upright-tilt testing. The cost of diagnostic 
testing in these patients was limited to the cost of 
an upright-tilt test ($453), thereby saving the cost 
of additional diagnostic studies. 
Limitations 
There are two limitations to this study. First, the 
type of patients referred to a university medical 
center depends on local referral patterns and the 
sophistication of referring physicians. Although ap- 
proximately 20% of the patients referred to our hos- 
pital had a history typical of vasodepressor synco- 
pe, this percentage may be higher or lower at other 
medical centers. However, the University of Michi- 
gan is a typical referral center, with patients being 
referred by a wide range of physicians, including 
general practitioners, internists, and cardiologists, 
and there is no reason to believe that our population 
of patients differs significantly from that at other 
large medical centers. 
A second limitation of this study is that only the 
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costs of major diagnostic tests were included for 
analysis. Minor diagnostic tests, the cost of consul- 
tations, and hospital charges were not included, in 
part because of the difficulty in accurately deter- 
mining these costs. Therefore, this study underesti- 
mates the potential cost savings of a heightened 
awareness of the clinical features of vasodepressor 
syncope. 
A third limitation of this study is that no gold 
standard exists for establishing a diagnosis of vaso- 
depressor syncope. Although the criteria used to 
establish a diagnosis of vasodepressor syncope in 
this study are conservative, these criteria have not 
been independently validated. 
Clinical Implications 
Based on the results of this study, the following 
approach to patients with syncope can be recom- 
mended. Patients with a history typical of vaso- 
depressor syncope should have the diagnosis estab- 
lished on a clinical basis at the time of their initial 
evaluation. If the patient has a normal physical ex- 
amination result, a normal electrocardiogram, and 
no history of cardiac disease, and the syncopal epi- 
sode was associated with a precipitant, a prodromal 
period, and no significant injury, no further evalua- 
tion or therapy may be necessary. If prophylactic 
pharmacologic therapy is appropriate to prevent 
recurrences of syncope, upright-tilt testing may be 
useful in guiding further therapy [12]. Several re- 
cent studies have demonstrated that pharmacologic 
agents such as p blockers and disopyramide may be 
helpful in preventing recurrent vasodepressor syn- 
cope [12,27]. 
Upright-tilt testing is appropriate as the initial 
diagnostic test in patients without clinical evidence 
of heart disease whose symptoms are consistent 
with, but not entirely typical of, vasodepressor syn- 
cope. For example, a patient may have had typical 
residual symptoms but no prodromal symptoms at 
the time of syncope. If the patient’s clinical symp- 
toms are reproduced, further neurologic and/or car- 
diovascular evaluation can be avoided. 
Patients whose history is not suggestive of vaso- 
depressor syncope should be evaluated in a stan- 
dard fashion, with the type and extent of diagnostic 
testing guided by the history, physical examination, 
and electrocardiogram [19]. For instance, the pa- 
tient with a prior myocardial infarction and im- 
paired ventricular function who experiences synco- 
pe without prodromal or residual symptoms and 
whose electrocardiogram demonstrates a bundle- 
branch block should be considered for electrophysi- 
ologic testing because the likelihood of detecting a 
potentially life-threatening arrhythmia such as 
ventricular tachycardia in this type of patient is 
high [28]. 
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